Clinical Research Directory
Browse clinical research sites, groups, and studies.
Berberine Improving Cognitive Impairments in Schizophrenia
Sponsor: Tianjin Anding Hospital
Summary
This study is a 12-week, randomized, blank-controlled, assessor-blinded trial. Eligible patients were randomized in a 1:1 ratio to receive either berberine hydrochloride or blank control as an add on to their stable antipsychotic regimen for 12 weeks. Randomization was performed using a computer-generated random number table, and allocation was concealed using sequentially numbered, opaque, sealed envelopes. The trial included four visits: baseline (visit 1), week 4 (visit 2), week 8 (visit 3) and week 12 (visit 4). Patients in the berberine group received berberine hydrochloride tablets (100 mg/tablet), three tablets three times daily. The control group received no intervention (blank control) and continued their usual care.
Official title: Study on the Mechanism s of Berberine Improving Cognitive Impairments in Schizophrenia Based on Gut-brain Axis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2023-07-21
Completion Date
2026-04-23
Last Updated
2026-06-30
Healthy Volunteers
No
Conditions
Interventions
Berberine
Patients in the berberine group received berberine hydrochloride tablets (100 mg/tablet), three tablets three times daily.
Locations (1)
Tianjin Anding Hospital
Tianjin, China